Organofluorides

Global High-performance Plastics Markets in Industrial Applications, 2027 - Investment in New Product Development to Accelerate the Transition to Industry 4.0/5.0 - ResearchAndMarkets.com

Retrieved on:

Tuesday, February 16, 2021

Chemicals, Plastics, Manufacturing, Chemistry, Physical sciences, Natural sciences, Thermoplastics, Organofluorides, Functional groups, Plastics, Monomers, Fluoropolymer, Ketone, Tetrafluoroethylene, Ether

The "Automation Driving the Demand for High-performance Plastics in Industrial Applications, 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Automation Driving the Demand for High-performance Plastics in Industrial Applications, 2027" report has been added to ResearchAndMarkets.com's offering.
Fluoropolymers considered in this study include poly tetraflouroethylene (PTFE), polyvinylidene fluoride (PVDF), ethylene tetrafluoroethylene (ETFE), and fluorinated ethylene propylene (FEP).
Ether ketones considered in this study include polyether ether ketone (PEEK), polyether ketone (PEK) and polyaryl ether ketone (PAEK).
HPP Market in Industrial Applications, Scope of Analysis
Revenue and Volume Shipment Forecast, HPP in Industrial Applications
Revenue Forecast by HPP Chemistry, HPP in Industrial Applications
Revenue Forecast Analysis by Region, HPP in Industrial Applications
Pricing Trends and Forecast Assumptions, Fluoropolymers
Revenue and Volume Shipment Forecast, Fluoropolymers
Volume Shipment Forecast by Chemistry, Fluoropolymers
Volume Shipment Forecast by Industry, Fluoropolymers
Revenue and Volume Forecast Analysis, Fluoropolymers
Volume Shipment Forecast by Region, Fluoropolymers
Revenue and Volume Shipment Forecast Analysis by Region, Fluoropolymers
Pricing Trends and Forecast Assumptions, Ether Ketones
Revenue and Volume Shipment Forecast, Ether Ketones
Volume Shipment Forecast by Chemistry, Ether Ketones
Volume Shipment Forecast by Industry, Ether Ketones
Revenue and Volume Shipment Forecast, Ether Ketones
Volume Shipment Forecast by Region, Ether Ketones
Revenue and Volume Shipment Forecast Analysis by Region, Ether Ketones
Pricing Trends and Forecast Assumptions, Polyarylsulfones
Revenue and Volume Shipment Forecast, Polyarylsulfones
Volume Shipment Forecast by Chemistry, Polyarylsulfones
Revenue and Volume Shipment Forecast Analysis, Polyarylsulfones
Volume Shipment Forecast by Region, Polyarylsulfones
Revenue and Volume Shipment Forecast Analysis by Region, Polyarylsulfones
Pricing Trends and Forecast Assumptions, Polyphenylene Sulfide
Revenue and Volume Shipment Forecast, Polyphenylene Sulfide
Revenue and Volume Shipment Forecast Analysis, Polyphenylene Sulfide
Volume Shipment Forecast by Region, Polyphenylene Sulfide
Revenue and Volume Shipment Forecast Analysis by Region, Polyphenylene Sulfide
Growth Opportunity 1 - Investment in Protection of Manufacturing Equipment for Increased Production Efficiency, 2020
Growth Opportunity 2 - Investment in New Product Development to Accelerate the Transition to Industry 4.0/5.0, 2020

Polyvinylidene Fluoride (PVDF) Market Players Gain Prodigious Sales Opportunities Owing to Numerous Properties of PVDF: TMR

Retrieved on:

Monday, February 15, 2021

Chemistry, Physical sciences, Materials, Thermoplastics, Plastics, Fluoropolymers, Organofluorides, Ferroelectric materials, Polyvinylidene fluoride, Fluorine, Clarification and stabilization of wine

Analysts at Transparency Market Research (TMR) are of the opinion that the global polyvinylidene fluoride (PVDF) market will demonstrate growth at a moderate CAGR of 9.1% during the forecast period 20192027.

Key Points:

Analysts at Transparency Market Research (TMR) are of the opinion that the global polyvinylidene fluoride (PVDF) market will demonstrate growth at a moderate CAGR of 9.1% during the forecast period 20192027.
Request for Covid-19 Impact Analysis on Polyvinylidene Fluoride (PVDF) Market: https://www.transparencymarketresearch.com/Covid19.php
Polyvinylidene fluoride (PVDF) is gaining impetus across a wide range of industries owing to its numerous advantages including high thermal stability and good chemical resistance.
On the grounds of all these applications, the global polyvinylidene fluoride (PVDF) market is foreseen to gather prodigious expansion avenues in the forthcoming years.
On the back of this factor, the global the polyvinylidene fluoride (PVDF) market is projected to experience prodigious sales opportunities in the years ahead.

Polyvinylidene Fluoride (PVDF) Market Players Gain Prodigious Sales Opportunities Owing to Numerous Properties of PVDF: TMR

Retrieved on:

Monday, February 15, 2021

Chemistry, Organic polymers, Physical sciences, Plastics, Thermoplastics, Organofluorides, Fluoropolymers, Ferroelectric materials, Polyvinylidene fluoride, Polyvinyl chloride, Fluorine

- With increasing demand for polyvinylidene fluoride (PVDF) from end-use industries, many players in the polyvinylidene fluoride (PVDF) market are focused on expanding their production capabilities.

Key Points:

- With increasing demand for polyvinylidene fluoride (PVDF) from end-use industries, many players in the polyvinylidene fluoride (PVDF) market are focused on expanding their production capabilities.
Analysts at Transparency Market Research (TMR) are of the opinion that the global polyvinylidene fluoride (PVDF) market will demonstrate growth at a moderate CAGR of 9.1% during the forecast period 20192027.
On the back of this factor, the global the polyvinylidene fluoride (PVDF) market is projected to experience prodigious sales opportunities in the years ahead.
The list of key players in the polyvinylidene fluoride (PVDF) market includes following names:

Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma

Retrieved on:

Wednesday, February 10, 2021

Biotechnology, Hospitals, Health, Pharmaceutical, Oncology, Organofluorides, Drugs, COVID-19, COVID-19 drug development, Dexamethasone, Otologicals, Pregnanes, Health sciences, Chemistry

Patients with relapsed or refractory LBCL received dexamethasone 10 mg orally on the day of Yescarta infusion and each of the two following days.

Key Points:

Patients with relapsed or refractory LBCL received dexamethasone 10 mg orally on the day of Yescarta infusion and each of the two following days.
This analysis provided a more robust comparison of the safety, efficacy and pharmacokinetic/pharmacodynamic profiles of Cohort 6 with pivotal cohorts.
The propensity score-matching analysis suggested that response rates in Cohort 6 were comparable to those observed in the pivotal cohorts.
Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.

Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting

Retrieved on:

Monday, February 8, 2021

Glucocorticoids, Organofluorides, Medicine, Chemistry, Chemical compounds, Pregnanes, Acetonides, Diketones, Macular edema, Triamcinolone acetonide, Uveitis, Macula of retina

Favorable results from preclinical studies of a triamcinolone acetonide suspension translated to favorable clinical trial results for macular edema associated with non-infectious uveitis.

Key Points:

Favorable results from preclinical studies of a triamcinolone acetonide suspension translated to favorable clinical trial results for macular edema associated with non-infectious uveitis.
In this analysis, 93,756 patient eyes were assessed from de-identified medical records from hundreds of retina specialists across the United States.
These forward-looking statements include statements regarding the clinical development and the potential benefits of CLS-TA and therapies using Clearsides SCS Microinjector.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.

Provectus Biopharmaceuticals Announces Release of Preprint Manuscript Describing Preclinical Study of PV-10® Immunotherapy and Chemotherapy for Treatment of Pancreatic Cancer

Retrieved on:

Wednesday, January 20, 2021

Clinical medicine, Medicine, Cancer, Cancer treatments, Gemcitabine, Organofluorides, Pancreatic cancer, Chemotherapy regimen, Chemotherapy, Pancreatic tumor, Evofosfamide

Chemotherapy regimens that include gemcitabine are the standard of care for the treatment of pancreatic cancer.

Key Points:

Chemotherapy regimens that include gemcitabine are the standard of care for the treatment of pancreatic cancer.
The manuscript, entitled Intralesional injection of Rose Bengal augments the efficacy of gemcitabine chemotherapy against pancreatic tumors, is available at the following link: https://assets.researchsquare.com/files/rs-140621/v1/cb1df721-b58b-4f5d-... .
PV-10 treatment-mediated DAMP-release has been demonstrated in three different tumor types: melanoma, colon cancer, and now pancreatic cancer.
This suggested that increased pancreatic tumor burden, which diminished gemcitabine efficacy, was overcome when PV-10 was combined with gemcitabine.

InCarda Therapeutics Announces Enrollment of First U.S. Patient in Phase 2 INSTANT Trial of InRhythm™ for Treatment of Atrial Fibrillation

Retrieved on:

Tuesday, January 19, 2021

Antiarrhythmic agents, Chemical compounds, Sodium channel blockers, Benzamides, Flecainide, Organofluorides, Piperidines, Organic compounds, Chemistry

The results from the dose-ranging stage of the trial were recently presented at the American Heart Associations (AHA) Scientific Sessions 2020.

Key Points:

The results from the dose-ranging stage of the trial were recently presented at the American Heart Associations (AHA) Scientific Sessions 2020.
InCarda Therapeutics in collaboration with clinical investigators reported that oral inhaled flecainide can safely and rapidly convert recent-onset PAF to normal sinus rhythm (NSR).
InCarda is currently conducting the INSTANT Phase 2 trial of InRhythm in patients with recent-onset PAF.
The companyslead development product, InRhythm, is in Phase 2 development to treat acute episodes of PAF, a prevalent atrial arrhythmia.

NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer

Retrieved on:

Friday, January 15, 2021

Pyrimidines, Drugs, Chemical compounds, Organofluorides, Prodrugs, Thymidylate synthase, Capecitabine, Fluorouracil, Colorectal cancer

NuTide:302 is a three-part study investigating NUC-3373, NuCanas targeted thymidylate synthase inhibitor, in heavily pre-treated patients with metastatic colorectal cancer.

Key Points:

NuTide:302 is a three-part study investigating NUC-3373, NuCanas targeted thymidylate synthase inhibitor, in heavily pre-treated patients with metastatic colorectal cancer.
The ASCO GI presentation highlighted data from 37 patients treated in Part I of the study who received NUC-3373 either as monotherapy or in combination with leucovorin.
Many patients achieved longer progression-free survival on NUC-3373 than they had on their prior line of therapy and five patients experienced tumor shrinkage.
Our objective is to replace 5-FU and capecitabine with NUC-3373 as the backbone of treatment for patients with colorectal cancer.

New Jersey American Water Receives Leading Infrastructure Project Award from New Jersey’s Alliance for Action

Retrieved on:

Thursday, January 14, 2021

New Jersey American Water will be honored with a Leading Infrastructure Project Award from the New Jersey Alliance for Action.

Key Points:

New Jersey American Water will be honored with a Leading Infrastructure Project Award from the New Jersey Alliance for Action.
The award will be presented to the company virtually at the 10th Annual Leading Infrastructure Project Awards on February 17, 2021.
New Jersey American Water is a proactive leader in designing and testing new ways to effectively treat emerging compounds including Per- and Polyfluoroalkyl Substances (PFAS), stated Mike Wolan, Manager of Engineering, New Jersey American Water.
New Jersey American Water, a subsidiary of American Water (NYSE: AWK), is the largest investor-owned water utility in the state, providing high-quality and reliable water and/or wastewater services to approximately 2.8 million people.

Addex to Present at the Baader Helvea Swiss Equities Conference

Retrieved on:

Tuesday, January 12, 2021

Enzyme kinetics, Organic compounds, Chemistry, Branches of biology, Dipraglurant, Imidazopyridines, Organofluorides, Allosteric regulation, ASD, Dystonia, Allosteric modulator, Blepharospasm

Geneva, Switzerland, January 12, 2021- Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer,is scheduled to participate in the virtual Baader Helvea Swiss Equities Conference taking place on January 13 January 15, 2021.

Key Points:

Geneva, Switzerland, January 12, 2021- Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer,is scheduled to participate in the virtual Baader Helvea Swiss Equities Conference taking place on January 13 January 15, 2021.
He will be available for virtual one-on-one meetings throughout the conference.
Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in H1 2021.